Table of Contents Author Guidelines Submit a Manuscript
Canadian Journal of Infectious Diseases and Medical Microbiology
Volume 2017 (2017), Article ID 3948626, 6 pages
https://doi.org/10.1155/2017/3948626
Research Article

In Vitro Activity of Iclaprim against Methicillin-Resistant Staphylococcus aureus Nonsusceptible to Daptomycin, Linezolid, or Vancomycin: A Pilot Study

1Motif BioSciences, New York, NY, USA
2Rutgers New Jersey Medical School, Trenton, NY, USA
3IHMA Europe Sàrl, Route de I’Ile-au-Bois 1A, 1870 Monthey, Valais, Switzerland
4Department of Bacteriology, University of Glasgow Medical School, Glasgow, UK
5IHMA, Schaumburg, IL, USA

Correspondence should be addressed to David B. Huang; moc.oibfitom@gnauh.divad

Received 31 July 2017; Revised 18 October 2017; Accepted 2 November 2017; Published 17 December 2017

Academic Editor: Paul-Louis Woerther

Copyright © 2017 David B. Huang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. H. S. Sader, T. R. Fritsche, and R. N. Jones, “Potency and bactericidal activity of iclaprim against recent clinical gram-positive isolates,” Antimicrobial Agents and Chemotherapy, vol. 53, no. 5, pp. 2171–2175, 2009. View at Publisher · View at Google Scholar · View at Scopus
  2. P. Schneider, S. Hawser, and K. Islam, “Iclaprim, a novel diaminopyrimidine with potent activity on trimethoprim sensitive and resistant bacteria,” Bioorganic and Medicinal Chemistry Letters, vol. 13, no. 23, pp. 4217–4221, 2003. View at Publisher · View at Google Scholar · View at Scopus
  3. H. Laue, T. Valensise, A. Seguin, S. Lociuro, K. Islam, and S. Hawser, “In vitro bactericidal activity of iclaprim in human plasma,” Antimicrobial Agents and Chemotherapy, vol. 53, no. 10, pp. 4542–4544, 2009. View at Publisher · View at Google Scholar · View at Scopus
  4. C. G. Gemmell and G. Middlemas, “AR-100, a novel diaminopyrimidine: activity against various clinical isolates of gram-positive and gram-negative bacteria,” September 2002. View at Google Scholar
  5. CLSI M100-S25, Performance Standards for Antimicrobial Susceptibility Testing: 25th Informational Supplement, Clinical and Laboratory Standards Institute, Wayne, PA, USA, 2015.
  6. D. B. Huang and T. L. Lodise, “Use of pharmacokinetic/pharmacodynamics (PK/PD) analyses to determine the optimal fixed dosing regimen of iclaprim for Phase III ABSSSI clinical trials,” October 2016. View at Google Scholar
  7. L. Z Cui, E. Tominaga, H. Neoh, and K. Hiramatsu, “Correlation between reduced daptomycin susceptibility and vancomycin resistance in vancomycin-intermediate Staphylococcus aureus,” Antimicrobial Agents and Chemotherapy, vol. 50, no. 3, pp. 1079–1082, 2006. View at Publisher · View at Google Scholar · View at Scopus
  8. L. Z. Cui, X. Ma, K. Sato et al., “Cell wall thickening is a common feature of vancomycin resistance in Staphylococcus aureus,” Journal of Clinical Microbiology, vol. 41, no. 1, pp. 5–14, 2003. View at Publisher · View at Google Scholar · View at Scopus
  9. H. C. Neu and T. D. Gootz, “Antimicrobial chemotherapy,” in Medical Microbiology, S. Baron, Ed., University of Texas Medical Branch at Galveston, Galveston, TX, USA, 4th edition edition, 1996. View at Google Scholar
  10. D. L. Stevens, A. L. Bisno, H. F. Chambers et al., “Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America,” Clinical Infectious Diseases, vol. 59, no. 2, pp. 147–159, 2014. View at Publisher · View at Google Scholar · View at Scopus
  11. M. Bassetti, E. Righi, and A. Carnelutti, “New therapeutic options for skin and soft tissue infections,” Current Opinion in Infectious Diseases, vol. 29, no. 2, pp. 99–108, 2016. View at Publisher · View at Google Scholar · View at Scopus
  12. J. Edelsberg, A. Berger, D. J. Weber, R. Mallick, A. Kuznik, and G. Oster, “Clinical and economic consequences of failure of initial antibiotic therapy for hospitalized patients with complicated skin and skin-structure infections,” Infection Control and Hospital Epidemiology, vol. 29, no. 2, pp. 160–169, 2008. View at Publisher · View at Google Scholar · View at Scopus
  13. K. J. Eagye, A. Kim, S. Laohavaleeson, J. L. Kuti, and D. P. Nicolau, “Surgical site infections: does inadequate antibiotic therapy affect patient outcomes?” Surgical Infections, vol. 10, no. 4, pp. 323–331, 2009. View at Publisher · View at Google Scholar · View at Scopus
  14. E. Nannini, B. E. Murray, and C. A. Arias, “Resistance or decreased susceptibility to glycopeptides, daptomycin, and linezolid in methicillin-resistant Staphylococcus aureus,” Current Opinion in Pharmacology, vol. 10, no. 5, pp. 516–521, 2010. View at Publisher · View at Google Scholar · View at Scopus